VE303 receives Fast Track designation for prevention of recurrent C. difficile infection ahead of global pivotal Phase 3 study
Exploratory analyses from the VE303 Phase 2 CONSORTIUM study identify. | May 9, 2023
Financing will enable pivotal Phase 3 study of VE303 for recurrent C. difficile infection, to begin by 3Q 2023
Funds will also support Phase 2 study of VE202 for ulcerative colitis, to begin in 2Q. | April 25, 2023
Acurx Pharmaceuticals CEO David Luci tells Soulstring Media Group why he thinks his company and lead drug candidate, Ibezapolstat, can be a front-line treatment against C. difficile
New York, New York (Newsfile
The Clostridium difficile infection market is anticipated to surge owing to the launch of emerging therapies. The potential emerging treatment expected to launch in the forecast period includes
– Summarized data from the study s secondary endpoints show investigational oral microbiome therapeutic rapidly and durably lowered risk of recurrent C. difficile infection –
. | October 19, 2022